ArticlePloS one2025

Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis.

Alica Kubesch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.